Dogwood Therapeutics DWTX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's additional paid-in capital?
- Dogwood Therapeutics (DWTX) reported additional paid-in capital of $195.7M in Q1 2026.
- How has Dogwood Therapeutics's additional paid-in capital changed year-over-year?
- Dogwood Therapeutics's additional paid-in capital increased by 175.9% year-over-year, from $70.94M to $195.7M.
- What is the long-term trend for Dogwood Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Dogwood Therapeutics's additional paid-in capital has grown at a 26.0% compound annual growth rate (CAGR), from $57.91M to $183.86M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.